AndroGel Competitors Enter US After Perrigo’s Exclusivity Expires
Executive Summary
Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.
You may also be interested in...
Perrigo Persists On Pepcid As Prescription Profit Plummets
Perrigo has won a US appeals court ruling on its generic version of Pepcid Complete. However, the company’s Prescription generics business saw a 15% drop in sales and a 28% decline in operating profit as the firm reported its 2018 results, ahead of plans to separate the Prescription unit from the company as it transitions to become a ‘self-care’ company.
Perrigo’s new leader backs generics plans
Perrigo’s newly-appointed president and chief executive officer, Murray Kessler, has backed the planned ‘separation’of the firm’s ‘Rx’ Prescription US generics operation, but has also praised the business’ potential, albeit in the face of a disappointing financial third quarter.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.